How to Get GLP-1 Medications Covered by Insurance

GLP-1 medications represent the most significant advance in obesity medicine in decades — but their list prices put them beyond reach for the average patient without insurance coverage. The good news is that the coverage landscape has improved substantially since 2023, driven by the SELECT cardiovascular outcome trial and the resulting Medicare Part D expansion. The more important news is that insurance denial is frequently not the final word. Understanding how the coverage system works — what criteria insurers use, what documentation strengthens your case, and how to navigate the appeals process — gives most patients a realistic path to affordable access.

~50%

of large employer health plans cover at least one GLP-1 weight-loss medication as of 2025

~40%

of insurance appeals for GLP-1 medications are reversed on first appeal when properly documented

2023

Medicare Part D began covering Wegovy for cardiovascular disease patients following the SELECT trial

$25/mo

minimum cost with Novo Nordisk or Eli Lilly savings card for eligible commercially insured patients

The Coverage Landscape: What You’re Actually Dealing With

Insurance coverage for GLP-1 medications is genuinely inconsistent — and inconsistent in ways that feel arbitrary to patients. The same medication can be covered with a $25 copay on one insurance plan and flatly denied on another, even for patients with identical clinical profiles. Understanding why this happens is the first step to navigating it effectively.

The core issue is indication versus off-label use. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound are approved for chronic weight management. Most insurance plans cover diabetes medications far more broadly than they cover obesity medications. This means a patient who receives Ozempic for type 2 diabetes has a very different coverage experience than a patient receiving Wegovy for obesity — even though the molecules are identical in the case of Ozempic vs. Wegovy (both are semaglutide).

Why GLP-1 Coverage Is So Variable: The Core Problem

Obesity is not universally treated as a covered medical condition. Despite being classified as a chronic disease by the AMA, the CDC, and the WHO, many insurance policies still treat obesity as a lifestyle or cosmetic issue and exclude weight-loss medications from coverage. This is the fundamental policy barrier — and it is changing, but unevenly.

State law variation: Some states mandate obesity medication coverage; most do not. Your state of residence affects what your insurer is legally required to cover.
Employer self-insurance: Many large employers self-insure (meaning they pay claims directly and hire an insurer only to administer the plan). Self-insured plans are governed by federal ERISA law and are exempt from state insurance mandates — making coverage decisions entirely at the employer’s discretion.
Formulary tier placement: Even when covered, GLP-1s are often placed on specialty or Tier 4/5 formulary tiers, resulting in very high copays unless prior authorization establishes medical necessity.
The diabetes/obesity split: Ozempic (for diabetes) is often covered under medical benefits with standard copays; Wegovy (for obesity) is often excluded or placed on a separate, less-covered benefit tier even though the molecule is identical.

Who Qualifies for GLP-1 Coverage: The Standard Criteria

Most insurance plans that do cover GLP-1 medications for weight management use a similar set of eligibility criteria derived from the FDA’s approved indications. Meeting these criteria is the baseline for any coverage application — and the documentation you provide to your insurer needs to clearly demonstrate that you meet them.

Criterion	Standard Requirement	Notes for Your Application
BMI threshold (obesity indication)	BMI ≥30 kg/m² OR BMI ≥27 kg/m² with at least one weight-related comorbidity	Your physician must document current BMI measurement with date. Height and weight measurements from the same visit are ideal.
Weight-related comorbidities	Hypertension, type 2 diabetes or pre-diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease	Each comorbidity should be formally documented in your chart with diagnosis codes (ICD-10). E.g., hypertension = I10, T2D = E11.
Prior weight-loss attempts	Documentation of failed attempts with lifestyle modification (diet + exercise programmes) lasting typically 3–6 months	Most insurers require documented evidence of previous supervised diet and exercise programme. Your physician should note this in their letter — even informal attempts should be charted.
Contraindications absent	No personal or family history of MTC or MEN2; no active pancreatitis; not pregnant	Standard contraindications must be confirmed absent. Your physician confirms this as part of the prior auth submission.
Prescribing physician type	Some plans require prescriber to be a primary care physician, endocrinologist, or bariatric specialist — not a telehealth provider	Check your plan’s PA criteria carefully. Some telehealth prescriptions are not accepted for PA. If this is an issue, see your PCP for the prescription.
Step therapy (fail-first)	Some plans require failure of a lower-cost GLP-1 first (e.g., liraglutide/Saxenda before Wegovy)	Document any previous GLP-1 trials and outcomes. If you switched due to side effects, this must be explicitly noted — “adverse reaction” to a prior agent typically qualifies as a step-therapy exception.

💡

The Magic Phrase: “Medically Necessary for Comorbidity Management”

Insurance coverage is far more likely when GLP-1 therapy is framed as treatment for a documented metabolic condition — not as a weight-loss medication. If your physician’s letter says “this patient needs Wegovy for weight loss,” many insurers will deny it automatically. If the letter says “this patient has hypertension, pre-diabetes, and dyslipidaemia attributable to obesity, and GLP-1 therapy is medically necessary for management of these conditions,” the clinical framing changes the coverage calculus entirely.

Coverage by Insurance Type: What to Expect

🏢

Employer-Sponsored (Commercial) Insurance

Variable Coverage

The largest and most variable category. Coverage depends almost entirely on what your employer chose to include in their benefits package. As of 2025, approximately 50% of large employers (500+ employees) cover at least one GLP-1 obesity medication, up from ~25% in 2022. Small employers (<50 employees) cover GLP-1s far less frequently. Your best first step is to call the member services number on your insurance card and ask directly: “Does my plan cover semaglutide (brand: Wegovy) or tirzepatide (brand: Zepbound) for chronic weight management under diagnosis code E66?” Get the answer in writing (request a reference number for the call).

Tip: If your employer plan excludes GLP-1s, ask your HR department whether the plan is being updated during the next open enrollment period — and submit a formal request advocating for coverage. Group employee requests have driven many employer plan updates.

🪀

Medicare Part D

Expanding Coverage

Medicare Part D plans historically excluded weight-loss medications. This changed in 2023 when Medicare began covering Wegovy for patients with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) following the SELECT trial’s 20% MACE reduction finding. This is a significant but narrow coverage pathway. Zepbound coverage under Medicare is still expanding. Medicare does NOT yet broadly cover GLP-1s for obesity alone without a qualifying cardiovascular or diabetic indication. Patients with type 2 diabetes covered under Medicare Part D may have Ozempic or Mounjaro covered under their diabetes medication benefit, which is a separate and often more accessible pathway.

Tip: If you have Medicare and established CVD, specifically request coverage under the “cardiovascular risk reduction” indication for Wegovy rather than the obesity indication. These are distinct coverage pathways and the CVD pathway has broader Medicare coverage.

🏛️

Medicaid

State-Dependent

Medicaid coverage for GLP-1 obesity medications varies enormously by state. Some states (including California, New York, and Illinois) have expanded Medicaid coverage to include GLP-1 medications for obesity with appropriate clinical documentation. Many states do not cover them for obesity but do cover them for type 2 diabetes. The federal government has signalled intent to expand GLP-1 access through Medicaid but implementation is state-by-state. Check your specific state’s Medicaid preferred drug list (PDL) — available on your state’s Medicaid website — to determine which agents are covered and what criteria apply.

Tip: If your state Medicaid covers Ozempic for T2D but not Wegovy for obesity, and you have pre-diabetes or diabetes, your physician may be able to prescribe Ozempic for the diabetes indication at a dose sufficient for both glycaemic and weight-management purposes.

🏠

ACA Marketplace Plans

Plan-Specific

ACA marketplace (Obamacare exchange) plans vary significantly in whether they cover GLP-1 obesity medications. Bronze and Silver plans often have limited formularies that exclude specialty medications. Gold and Platinum plans are more likely to include GLP-1 coverage but at higher premium costs. During open enrollment, comparing formularies directly is critical — look up the specific drug on each plan’s formulary tool before enrolling. If GLP-1 coverage is important to you, it should be a primary criterion in plan selection. Some plans cover the diabetes-indication brands (Ozempic, Mounjaro) but not the obesity-indication brands (Wegovy, Zepbound), creating a possible pathway if you have a qualifying diabetes diagnosis.

Tip: Healthcare.gov’s plan comparison tool allows you to search by specific drug name. Use this during open enrollment to filter for plans that explicitly cover Wegovy or Zepbound before selecting a plan.

Prior Authorization: The Step-by-Step Process

Prior authorization (PA) is the formal process by which your insurance company evaluates a claim for a medication that requires advance approval before it will be covered. Virtually all insurers that do cover GLP-1 weight-management medications require prior authorization. Here is exactly how the process works and what you can do to maximise your chances of approval at each step.

Before Your Appointment

Confirm Your Plan’s Coverage and PA Criteria

Before you even see your doctor, call the member services number on your insurance card and ask: (a) Does my plan cover Wegovy (NDC: semaglutide 2.4mg) or Zepbound (tirzepatide 15mg) for chronic weight management under E66.09? (b) What are the prior authorisation criteria? (c) Is there a step-therapy requirement? (d) Who submits the PA — my doctor or me? Get a reference number for the call. Many insurers also post their PA criteria online in their “medical policy” or “coverage determination” documents — download the specific PA criteria for the drug you want before your appointment so your doctor knows exactly what to document.

Physician Visit

Build Your Clinical Record with Your Physician

Your medical chart is the foundation of every PA and appeal. At your appointment, ensure your physician documents: current BMI with date, all weight-related comorbidities with ICD-10 codes, previous weight-loss attempts and outcomes, discussion of dietary and lifestyle interventions tried, clinical rationale for GLP-1 therapy specifically (not just “weight loss” but the metabolic conditions driving the need), and confirmation that contraindications are absent. Many PA denials occur because the physician’s documentation did not match the insurer’s specific criteria language — bring the PA criteria document from step 1 to your appointment and walk through it with your doctor.

PA Submission

Your Doctor Submits the Prior Authorization

The PA is typically submitted by your physician’s office to your insurer, either electronically through the pharmacy benefit manager (PBM) or via fax with a PA form. Follow up with your doctor’s office 48 hours after the appointment to confirm the PA was actually submitted — practices vary in how promptly this is handled. Ask for the PA reference number so you can track status independently. Most insurers have a 15-business-day window to respond to a PA request (some states mandate faster timelines). You can call your insurer’s PA department directly to check status using the reference number. Urgent PA requests (expedited review) can be made if your physician certifies that the standard timeline would adversely affect your care.

Decision

Respond to the PA Decision

You will receive a written notice of the PA decision. If approved: confirm the approval period (typically 6–12 months) and the specific NDC code approved so your pharmacy fills the correct product. Renewal PA may be required annually — calendar this. If denied: the denial letter will include the reason for denial and your right to appeal. Do not simply accept a denial — denial reversal rates on first appeal are approximately 40% when the appeal is properly documented. Move to the appeal process (Section 6 below). If you need the medication urgently while appealing, ask your physician about a bridge prescription at a diabetes dose under a different indication, or explore the manufacturer savings card as a temporary solution.

The Documents You Need: A Complete Checklist

Every successful PA and appeal is built on thorough documentation. Here is the complete list of what you should compile before submitting a PA or appeal, with notes on what makes each document most effective:

Document	What It Must Show	Where to Get It
Physician’s letter of medical necessity	Current BMI; all weight-related diagnoses with ICD-10 codes; prior treatment history; clinical rationale specific to your comorbidities; explicit statement that GLP-1 therapy is medically necessary	Request specifically from your physician; provide them the insurer’s PA criteria language to reference
Recent clinical notes	Dated visit notes documenting BMI, comorbidities, and treatment discussion from within the past 3–6 months	Patient portal (MyChart, etc.) or direct request from physician’s office
Lab results	Recent HbA1c (if diabetic/pre-diabetic), lipid panel, blood pressure readings, and any metabolic labs supporting the comorbidity burden	Patient portal or lab results from recent visits
Comorbidity diagnosis records	Formal diagnoses of hypertension, T2D, dyslipidaemia, sleep apnoea, or cardiovascular disease with ICD-10 codes	Your chart; may need specific records request
Prior weight-loss treatment documentation	Evidence of supervised dietary and exercise interventions; previous medication trials; participation in weight-management programmes	Physician notes; receipts/records from dietary programmes; gym/personal trainer records if needed
Previous GLP-1 trial records (if applicable)	Documentation of what prior GLP-1 was used, at what dose, for how long, and why it was discontinued (adverse reaction, insufficient response)	Pharmacy records; physician prescribing notes
Peer-reviewed clinical evidence	Publications supporting GLP-1 efficacy for your specific indication (SELECT trial for CVD patients; STEP-1 for obesity; SURMOUNT-1 for tirzepatide)	PubMed or published abstracts; your physician may provide these
Insurer’s PA denial letter	Exact reason for denial; specific criteria not met (required for targeted appeal)	Sent by your insurer upon denial; keep every letter

If You’re Denied: Understanding Your Rights

A denial is not a final answer — it is the beginning of a process. Under federal law (ACA), you have the right to appeal any adverse coverage decision. Under most state laws, you have additional rights including the right to an independent external review. Here is what you need to know:

⚖️

Your Legal Rights After a Denial

The ACA requires all non-grandfathered health plans to provide: (1) a clear written explanation of the reason for denial, (2) the right to an internal appeal, (3) the right to an independent external review after exhausting internal appeals, and (4) expedited review for urgent care situations. Your insurer must tell you exactly which criteria your claim failed to meet — and your appeal must directly address those specific criteria. Vague appeals without addressing the denial reason are rarely successful.

Common Denial Reasons and How to Address Them

Denial Reason	What It Means	How to Address in Your Appeal
Not medically necessary	Insurer believes the clinical documentation doesn’t establish a medical need	Strengthen the letter of medical necessity; add explicit language about comorbidity management rather than weight loss per se; include peer-reviewed evidence supporting medical necessity for your specific diagnoses
Step therapy not completed	Plan requires you to have tried and failed a lower-cost medication first	Document any prior GLP-1 or weight-loss medication trials; if you haven’t tried the required drug, ask your physician whether a step-therapy exception applies (allergy, contraindication, or clinical reason the required drug is inappropriate for you)
BMI threshold not met	Plan has a higher BMI threshold than the FDA indication (e.g., plan requires BMI ≥35)	Provide dated measurements; document all weight-related comorbidities as these typically lower the threshold requirement; have physician argue clinical necessity given comorbidity burden even if BMI is in the borderline range
Not covered benefit (exclusion)	Plan simply doesn’t cover weight-loss medications	This requires a different approach: appeal on the basis that the medication is needed for a covered condition (e.g., cardiovascular risk reduction, pre-diabetes management) rather than for weight loss; get your physician to frame the primary indication accordingly
Prescriber not eligible	Plan requires specific prescriber type (PCP or specialist, not telehealth)	Obtain the prescription from your primary care physician or an endocrinologist; the clinical documentation from your telehealth provider can still support the application even if they cannot be the prescribing provider
Formulary non-preferred drug	Plan covers a GLP-1 but not the specific one requested (e.g., covers Saxenda but not Wegovy)	Document why the non-preferred drug is clinically appropriate for you; if you’ve had adverse reactions or insufficient response to the preferred drug, document this explicitly; ask physician to include a formulary exception request stating why the specific agent requested is medically necessary

How to Appeal a Denial: The Four-Stage Process

Most insurance denials can be challenged through a structured appeal process. Success rates improve substantially at each stage when you submit a well-documented, targeted appeal rather than a generic complaint. Here is the complete escalation pathway:

Internal Appeal (Level 1) — File Within 180 Days of Denial

The first appeal is submitted directly to your insurance company and reviewed by a different clinical reviewer than the one who issued the denial. This is your most important appeal. Address every criterion listed in the denial letter directly and provide the documentation checklist from Section 5. Submit the physician’s updated letter of medical necessity that specifically counters the denial reason. Include peer-reviewed evidence supporting your case. Many plans allow submission online, by fax, or by mail — use certified mail for paper submissions so you have proof of delivery. The insurer typically has 30–60 days to respond to a standard internal appeal, or 72 hours for an expedited (urgent) appeal.

▲ ~40% reversal rate at this stage with proper documentation

Internal Appeal (Level 2) — Some Plans Have a Second Internal Review

Depending on your plan, there may be a second level of internal appeal reviewed by a medical director or peer-to-peer review panel. A key opportunity at this stage is a peer-to-peer review — where your physician speaks directly with the insurer’s medical reviewer. Many denials are reversed at peer-to-peer when the treating physician can directly explain the clinical rationale. Ask your physician to request a peer-to-peer review call with the insurer’s medical director. This is particularly effective when the denial is based on “not medically necessary” rather than a plan exclusion.

▲ Peer-to-peer calls reverse approximately 25–35% of remaining denials

External Independent Review — Your Federal Right After Internal Exhaustion

After exhausting internal appeals, you have the federal right to an external review by an independent organization not affiliated with your insurer. The reviewer is typically a licensed physician or clinical professional in the relevant specialty. Submit all your documentation and clearly articulate why the denial was incorrect. External reviewers are not bound by your insurer’s policy language — they evaluate clinical appropriateness based on the evidence. Insurer compliance with external review decisions is generally required by state and federal law. Contact your State Insurance Commissioner to initiate external review if your insurer does not provide a clear pathway. Some states also allow you to file a complaint with the state insurance commissioner simultaneously, which can add regulatory pressure.

▲ External reviews overturn insurer decisions in approximately 25–45% of cases across all drug types

Patient Assistance & Escalation Resources

If the standard appeals process is exhausted, additional escalation channels include: State Insurance Commissioner complaint (creates a regulatory record and sometimes prompts insurer reconsideration); State Insurance Commissioner appeal mediation (available in some states); Patient advocacy organisations (Obesity Action Coalition, Patient Advocate Foundation) that provide case managers who navigate appeals on your behalf at no cost; Employer HR escalation (if employer-sponsored plan — your employer has leverage with the insurer); and legal consultation in rare cases where coverage denial appears to constitute discriminatory treatment under disability law or state insurance regulations.

▲ Patient advocacy involvement significantly improves outcomes across all stages

Appeal Letter Template: What to Say and How to Say It

Your appeal letter is the core of your case. It must be specific, clinical, and directly address the denial reason. Here is a professionally structured template that you can adapt with your specific details. Your physician should sign or co-sign this letter for maximum effect.

📄 Appeal Letter Template — Adapt with Your Specific Information

[Your Name]

[Your Member ID]

[Date]

Medical Appeals Department

[Insurance Company Name]

RE: Appeal of Prior Authorization Denial

Claim Reference: [Denial Reference Number]

Medication Requested: [Wegovy/Zepbound/Ozempic]

Dear Appeals Reviewer,

I am writing to formally appeal the denial of prior authorization for [medication name] (semaglutide/tirzepatide), dated [denial date]. The denial stated: [quote exact denial reason from letter].

I respectfully submit that this determination is incorrect for the following clinical reasons:

1. Medical Necessity for Comorbidity Management

I am a [age]-year-old patient with a BMI of [BMI] and the following weight-related comorbidities: [list all diagnoses with ICD-10 codes, e.g., “Hypertension (I10), Pre-diabetes (R73.09), Dyslipidaemia (E78.5)”]. GLP-1 therapy is medically necessary for the management of these conditions, which are directly attributable to and perpetuated by obesity. This treatment is not primarily cosmetic or elective — it is the standard of care for my clinical profile.

2. Prior Treatment History

I have previously attempted weight management through [list: dietary programme, caloric restriction, exercise programme, prior medications tried and outcomes]. These efforts produced [describe outcomes, e.g., “insufficient sustained weight loss”]. My physician has documented these attempts in my clinical record (enclosed).

3. Clinical Evidence Supporting This Treatment

The STEP-1 trial (Wilding et al., NEJM 2021) demonstrated ~15% average body weight reduction with semaglutide 2.4mg. The SELECT trial (Lincoff et al., NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events in patients with obesity and cardiovascular disease. This evidence directly supports the clinical appropriateness of GLP-1 therapy for my profile. [Add any additional trial references relevant to your specific comorbidities.]

4. Response to Specific Denial Criteria

[Address the exact denial criterion stated in your denial letter. E.g., if denied for “step therapy not completed”: “I have a documented adverse reaction to liraglutide (Saxenda), the required step-therapy medication, including persistent nausea requiring medical evaluation on [date]. This documented adverse reaction constitutes a clinical exception to the step-therapy requirement under [plan name]’s own exception criteria.]

Enclosed with this letter: Physician Letter of Medical Necessity, Recent Clinical Notes, Supporting Lab Results, [any additional documents].

I respectfully request an expedited review and reversal of this denial. Please contact my physician, [physician name] at [phone], to arrange a peer-to-peer review if required.

Sincerely,

[Your name and signature]

cc: [Physician name] / [Employer HR if applicable]

Medicare Coverage: The Full Picture

Medicare’s coverage of GLP-1 medications has evolved significantly and remains the area of most rapid change. Here is the current state as of early 2026:

Medicare Coverage Scenario	Coverage Status	Key Requirements
Wegovy (semaglutide 2.4mg) for CVD risk reduction	Covered	Must have established CVD: prior MI, stroke, or PAD. Obesity (BMI ≥27) required. Covered under Part D via SELECT indication. Requires PA at most plans.
Ozempic (semaglutide) for Type 2 Diabetes	Covered	Must have T2D diagnosis. Covered under Part D diabetes drug benefit. One of the most commonly covered GLP-1s under Medicare.
Mounjaro (tirzepatide) for Type 2 Diabetes	Covered	T2D diagnosis required. Part D drug benefit. Coverage breadth varies by specific Part D plan.
Zepbound (tirzepatide) for obesity only	Limited	Medicare does not broadly cover obesity medications without a qualifying indication. OSA indication may open a pathway for some plans. Expanding but not yet uniform.
Wegovy for obesity only (no CVD)	Generally Not Covered	Medicare Part D excluded weight-loss drugs for obesity without CVD or diabetes. Legislative change pending but not yet enacted broadly.
Medicare Advantage Plans	Plan-Specific	Medicare Advantage (Part C) plans vary. Some offer supplemental drug benefits that cover obesity medications. Check your specific MA plan formulary.

The Medicare CVD Coverage Pathway: Your Best Route if Eligible

If you have Medicare and have a history of heart attack, stroke, or peripheral artery disease — and have a BMI of 27 or above — you qualify for the SELECT-based Wegovy coverage pathway. This requires your physician to document your cardiovascular diagnosis explicitly and submit a PA with the cardiovascular risk-reduction indication rather than the obesity indication. This is currently the most accessible GLP-1 pathway for Medicare beneficiaries.

20%

MACE reduction driving Medicare coverage

Employer & Self-Insured Plans: A Special Category

If your insurance comes through a large employer, there is an important structural reality you need to understand: many large employers are self-insured, meaning they pay medical claims directly and only hire an insurance company (like Aetna, Cigna, or UnitedHealthcare) to administer the plan. This matters because self-insured plans are governed by federal ERISA law and are largely exempt from state insurance mandates — meaning your employer has almost total discretion over what to cover.

How to Advocate for GLP-1 Coverage Through Your Employer

Talk to HR directly: Ask whether the plan is fully-insured or self-insured, and whether GLP-1 coverage is being considered. Many HR teams don’t know employee demand exists unless it’s raised explicitly.
Request during open enrollment: Benefits changes happen during annual benefit renewal cycles. Submit a formal written request for GLP-1 coverage inclusion during the benefit renewal period (typically Q3–Q4 of each year).
Organise with colleagues: Employers respond to employee group requests more than individual ones. If you know other employees who would benefit from GLP-1 coverage, a coordinated request to HR carries more weight than a single request.
Frame it as an employer ROI argument: Employers who cover GLP-1 medications have documented reductions in cardiovascular events, T2D-related medical costs, and disability claims. The cost of the medication may be offset by reduced downstream medical costs within 3–5 years. Providing this economic argument to HR strengthens the business case.
Reference the trend: As of 2025, more than 50% of large employers cover GLP-1 obesity medications. If your employer is in the minority that doesn’t, citing this competitive benefits landscape can be persuasive.
Request a formulary exception: Even within a self-insured plan that excludes GLP-1s as a formulary category, your HR plan administrator can grant individual formulary exceptions for documented medical necessity. This is more accessible than most employees realise.

Manufacturer Savings Programs: What They Actually Offer

Both Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) offer savings programs that can dramatically reduce out-of-pocket costs for patients with commercial insurance who do not qualify for public programs. These are not available to Medicare or Medicaid patients.

Program	Drug	Eligibility	Savings	How to Access
Wegovy Savings Card (Novo Nordisk)	Wegovy (semaglutide 2.4mg)	Commercially insured; not Medicare/Medicaid eligible; income-based for uninsured	As low as $25/mo for first 12 months; up to $500/prescription for eligible patients	WegovyCoPayCard.com; activated at pharmacy
Ozempic Savings Card (Novo Nordisk)	Ozempic (semaglutide 1–2mg)	Commercially insured; not Medicare/Medicaid	As low as $25/mo	Ozempic.com savings page
Lilly Insulin Value Program (Zepbound)	Zepbound (tirzepatide obesity)	Commercially insured; income thresholds apply	$25/mo or lower depending on coverage tier	ZepboundSavings.com
Mounjaro Savings Card (Eli Lilly)	Mounjaro (tirzepatide diabetes)	Commercially insured; not Medicare/Medicaid	$25–$150/mo depending on coverage	Mounjaro.com savings page
Novo Nordisk Patient Assistance (uninsured)	Wegovy, Ozempic	Uninsured or underinsured; income ≤400% federal poverty level	Free or very low cost medication	NovoCare Patient Assistance program
Lilly Cares Foundation	Zepbound, Mounjaro	Uninsured; income thresholds apply	Free medication for qualifying patients	LillyCares.com

⚠️

Savings Cards Have Limitations

Manufacturer savings cards are not available to patients with Medicare or Medicaid coverage. They often cover only a limited number of months (e.g., the first 12 months of therapy). Savings card availability can change, and some plans have policies that prevent using manufacturer cards alongside insurance. Always confirm current terms directly with the manufacturer programme before relying on these savings for long-term cost planning.

If All Else Fails: Accessible Alternatives to Brand-Name Coverage

If insurance coverage remains out of reach after exhausting the appeals process, these alternatives provide meaningful access to GLP-1 therapy at substantially lower cost than brand-name retail pricing.

💊

Compounded Semaglutide

$150–$350

per month via telehealth

FDA-permitted compounded semaglutide from licensed 503B compounding pharmacies. Same active molecule as Wegovy/Ozempic at significantly lower cost. Requires physician prescription through a telehealth or in-person provider. Access is through specialist GLP-1 telehealth platforms.

🧬

Compounded Tirzepatide

$200–$400

per month via telehealth

Compounded tirzepatide via licensed 503B pharmacies. Same active molecule as Mounjaro/Zepbound at a fraction of brand-name cost. Access is growing through telehealth GLP-1 platforms. Slightly less widespread than compounded semaglutide.

🇾

Canadian or International Pharmacies

$200–$600

per month (varies by country)

Brand-name semaglutide and tirzepatide are priced significantly lower in Canada and many European countries. Some patients obtain prescriptions from US physicians and use licensed Canadian pharmacies. Note: importation of prescription medications is technically regulated by FDA policy; consult a legal/medical professional before pursuing this route.

Access GLP-1 Therapy Without Insurance Barriers

Compare telehealth programmes offering physician-supervised semaglutide and tirzepatide — including compounded options starting at $150/month with full prescribing and monitoring support.

Compare GLP-1 Plans →

Frequently Asked Questions

Ozempic is FDA-approved for type 2 diabetes, not for weight loss — which means its insurance coverage is as a diabetes medication. Many plans that cover Ozempic for T2D will not cover it off-label for weight loss in patients who don’t have diabetes. If you have type 2 diabetes, Ozempic coverage is generally much more accessible than Wegovy because it falls under the standard diabetes drug benefit rather than an obesity-specific benefit. If you need a GLP-1 for weight loss and don’t have T2D, Wegovy (semaglutide 2.4mg) is the FDA-approved obesity indication product and the appropriate one for insurance applications. Some patients with both obesity and pre-diabetes successfully obtain Ozempic coverage by having the prescribing physician document pre-diabetes management as the primary indication alongside weight management.

Standard prior authorization requests have a legally mandated response window that varies by state, but federal law (ACA) requires a decision within 15 business days for standard PA and 72 hours for urgent (expedited) PA. In practice, many decisions come faster — often within 3–7 business days. However, if documentation is incomplete, the insurer may issue a “pending” notice requesting additional information, which restarts the clock. You can speed the process by: (1) ensuring your physician submits a complete PA with all required documentation on the first submission, (2) calling your insurer’s PA department 3–4 days after submission to confirm receipt and completeness, and (3) requesting expedited review if your physician can certify medical urgency. If you need the medication while waiting for PA, ask about the manufacturer’s savings card as a temporary bridge.

Yes, but only under specific circumstances. Following the SELECT trial, Medicare Part D plans now cover Wegovy for patients who have established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) AND obesity (BMI ≥27). This does not cover Wegovy for obesity alone without a qualifying cardiovascular indication. Medicare does not currently have broad coverage for GLP-1 medications as obesity treatments for patients without diabetes or cardiovascular disease — this would require federal legislative action. If you have Medicare and T2D, Ozempic and Mounjaro are more readily covered under the diabetes drug benefit. If you have Medicare and established CVD with obesity, Wegovy under the cardiovascular indication is your primary pathway. Check your specific Medicare Part D plan formulary, as coverage varies between plans.

After two internal appeal denials, request an external independent review — this is your federal right under the ACA. External reviewers are independent of your insurer and evaluate clinical appropriateness without being bound by your insurer’s internal policy language. Simultaneously, file a complaint with your state Insurance Commissioner, which creates a formal regulatory record and sometimes prompts insurer reconsideration. Contact a patient advocacy organisation: the Obesity Action Coalition (ObesityAction.org) and Patient Advocate Foundation (PatientAdvocate.org) provide free case managers who navigate insurance appeals specifically for obesity medications and have strong track records. If your plan is employer-sponsored, escalate to your employer’s HR department and explain that you have exhausted the insurer’s appeals process — employers have contractual leverage with their insurance carrier that individual patients do not. While pursuing the appeals, explore compounded GLP-1 options through telehealth as a cost-effective interim access route.

No, compounded medications are generally not covered by insurance. Compounded drugs are prepared by a licensed pharmacy for a specific patient rather than manufactured by a pharmaceutical company — they are not FDA-approved products, which is a requirement for most insurance formulary coverage. The value of compounded semaglutide and tirzepatide is their direct-pay low cost ($150–$400/month) rather than insurance coverage. Some flexible spending accounts (FSAs) or health savings accounts (HSAs) can be used to pay for compounded GLP-1 prescriptions with tax-advantaged dollars, which effectively provides a meaningful cost reduction. Check with your FSA/HSA administrator, as rules on eligibility for compounded medications vary.

In most cases, no — but there are important nuances. Manufacturer savings cards typically reduce your copay on an insurance-covered claim without affecting your benefits. However, in some plans, the amount paid by a manufacturer savings card does not count toward your deductible or out-of-pocket maximum (this is called an “accumulator adjustment” program, used by many PBMs). This means that after the savings card runs out or reaches its cap, you may suddenly face the full cost. Ask your insurer and pharmacist whether your plan uses an accumulator adjuster — and if so, budget for the full copay after your savings card period ends. Some states have passed laws limiting accumulator adjusters, so your state may provide additional protection. Medicare and Medicaid patients are not eligible for manufacturer savings cards under federal anti-kickback laws.

💵 The Bottom Line

A Denial Is the Start of the Process, Not the End.

GLP-1 insurance coverage is improving year by year — but it remains genuinely inconsistent, and the patients who navigate it successfully are almost universally those who understand the system, document their case thoroughly, and persist through the appeals process rather than accepting the initial denial as final. The core insight is this: insurance companies are not evaluating whether GLP-1 therapy is good medicine. They are evaluating whether your documented clinical case meets their specific coverage criteria. Your job, with your physician’s help, is to make that case compellingly and completely.

Start by confirming your plan’s actual coverage criteria — not what you assume they are, but what they specifically state. Build a clinical record with your physician that maps directly to those criteria. Submit a complete, well-documented PA on the first attempt. If denied, appeal — because approximately 40% of properly documented first appeals are reversed. If still denied, escalate to external review and patient advocacy resources. And while you are navigating the insurance system, compounded GLP-1 therapy through a physician-supervised telehealth programme provides a high-quality, significantly more affordable access pathway that many patients use as a bridge or as a permanent alternative.

Compare GLP-1 Programmes →